ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
40 announcements with these filters
Thyrocare Technologies Limited has granted 1,92,000 employee stock options to eligible employees under the company's approved stock option scheme.
Thyrocare's board approved sale of 100% in Nueclear Healthcare to Trovera for ~₹141.40 Crore. The move exits radiology to refocus on core pathology business.
API Holdings, successor to promoter Docon, released a full pledge over 7.95 crore Thyrocare shares after NCD redemption. No Docon shares remain encumbered.
API Holdings Limited reported an exempt acquisition of 8.12 crore shares (51.02%) of Thyrocare Technologies Limited, pursuant to the amalgamation of Docon Technologies Private Limited.
API Holdings acquired 8,12,00,000 shares (51.02%) of Thyrocare Technologies via a NCLT-approved scheme of amalgamation. The transfer resulted from the merger of Docon Technologies into API Holdings.
NCLT sanctioned the merger of Docon Technologies into API Holdings. Accordingly, the promoter's 51.02% stake in Thyrocare transfers to API Holdings, leaving the aggregate shareholding unchanged.
Thyrocare Technologies reported the termination of transaction documents and release of a share pledge following the full repayment of Rs.1,700 Crore NCDs by API Holdings.
Thyrocare informed the exchange of the full repayment of NCDs by its holding company API Holdings. Consequently, the share pledge on company equity is released.
ICICI Prudential Mutual Fund sold a 2.06% stake in Thyrocare Technologies through open market transactions. Its holding decreased from 5.33% to 3.27% of the company.
Docon Technologies Private Limited announced the release of a pledge over 1,75,00,000 equity shares of Thyrocare Technologies Ltd. The release occurred on August 11, 2026.
Promoter Docon Technologies sold 1,57,69,696 equity shares of Thyrocare Technologies. Promoter shareholding decreased from 60.92% to 51.02%.
Promoter Docon Technologies Private Limited has released a pledge on 1,75,00,000 equity shares of Thyrocare Technologies Ltd. The pledge was released by Catalyst Trusteeship Limited on August 11, 2026.
Thyrocare Q1 FY27: Consolidated revenue grew 24.3% YoY to INR 240 Cr, EBITDA margin expanded to 32.2%. Strategy shifts toward specialty diagnostics.
Thyrocare Technologies submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, in a machine-readable format as requested by the NSE.
Thyrocare Technologies Limited has re-appointed Ernst & Young LLP as its Internal Auditor for a term of 12 months. This is a routine governance update.
Thyrocare Technologies' Board has approved an in-principle evaluation of a potential demerger or business transfer involving the radiology undertaking of its subsidiary, Nueclear Healthcare Limited.
Thyrocare delivered strong Q1 FY27 results with 24% YoY consolidated revenue growth and 34% YoY PAT growth, driven by pathology network expansion and high-value specialty test launches.
Thyrocare Technologies Ltd reported revenue from operations of ₹240 Cr (+24.4% YoY) and net profit of ₹51.3 Cr (+33.9% YoY) for Q1 FY27.
Thyrocare Technologies scheduled a board meeting on July 23, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.
Thyrocare Technologies announced amendments to its Memorandum of Association. These changes were approved by members during the 26th Annual General Meeting.
Thyrocare appointed M/s. Price Waterhouse Chartered Accountants LLP as Statutory Auditors. This follows the term completion of M/s. M S K A & Associates LLP.
Thyrocare Technologies held its 26th AGM on June 30, 2026. All proposed ordinary and special resolutions were duly passed.
Thyrocare Technologies approved a ₹5.50 Crore cash equity infusion into its subsidiary, Think Health Diagnostics. The investment supports working capital and business operations through multiple tranches.
Docon Technologies reported a Rs.30 Crore partial redemption of NCDs linked to its share encumbrance in Thyrocare Technologies. The number of pledged shares remains unchanged.
Thyrocare Technologies convened its 26th Annual General Meeting for June 30, 2026. Agenda items include dividend declaration, director appointments, and MoA amendments for shareholder approval.
Thyrocare Technologies fixed June 23, 2026, as the record date for its ₹7.00 final dividend. Payment remains subject to shareholder approval at the upcoming June AGM.
Thyrocare Technologies Limited submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's environmental, social, and governance performance and initiatives.
Thyrocare Technologies submitted its FY 2025-26 Annual Report and 26th AGM notice. The meeting is scheduled for June 30, 2026.
Thyrocare reports strong Q4 FY26 results with 20% consolidated revenue growth and 128% PAT surge, driven by volume growth and core pathology expansion.
Thyrocare Technologies announced a leadership overhaul including the appointment of Price Waterhouse as statutory auditors and two new directors. CEO Rahul Guha was re-appointed for five years.